Results 41 to 50 of about 39,703 (285)
Background The ABC transporter P-glycoprotein (P-gp) is recognized as a site for drug-drug interactions and provides a mechanistic explanation for clinically relevant pharmacokinetic interactions with digoxin.
Michaëlsson Karl +4 more
doaj +1 more source
Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis [PDF]
BACKGROUND AND AIMS: The MDR1 gene encodes P-glycoprotein 170, an efflux transporter that is highly expressed in intestinal epithelial cells. The MDR1 exonic single nucleotide polymorphisms (SNPs) C3435T and G2677T have been shown to correlate with ...
Arnott, Ian D +7 more
core +1 more source
Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis
This review highlights the potential of organ‐on‐a‐chip systems for studying comorbidities, using chronic kidney disease (CKD) and osteoarthritis (OA) as examples. It summarizes recent advances in kidney‐on‐a‐chip and joint‐on‐a‐chip models and discusses their current and potential application in investigating CKD, OA, and CKD‐OA comorbidity, aiming to
Mingying Han +7 more
wiley +1 more source
Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta [PDF]
Despite numerous examples of the effects of the human gastrointestinal microbiome on drug efficacy and toxicity, there is often an incomplete understanding of the underlying mechanisms. Here, we dissect the inactivation of the cardiac drug digoxin by the
Balskus, Emily Patricia +5 more
core +1 more source
This study employed tRNASUAG, an anticodon‐engineered tRNA (ACE‐tRNA), to introduce a phosphorylatable serine into the C‐terminal domain of HBc by reading through its stop codon, thereby potentially promoting the ubiquitin‐proteasome degradation of HBc, and subsequently inhibiting HBV replication. Through a tRNASUAG‐gHBV1‐tRNASUAG‐gHBV2‐tRNASUAG tandem
Xingwen Yang +7 more
wiley +1 more source
Background Digoxin acutely increases cardiac output in patients with pulmonary arterial hypertension (PAH) and right ventricular failure; however, the effects of chronic digoxin use in PAH are unclear.
Kevin Y. Chang +8 more
doaj +1 more source
Randomised controlled trial of specialist nurse intervention in heart failure [PDF]
<p>Objectives. To determine whether specialist nurse intervention improves outcome in patients with chronic heart failure.</p> <p>Design. Randomised controlled trial.</p> <p>Setting.
Blue, L. +11 more
core +2 more sources
Potentiating Cerebral Perfusion Normalizes Glymphatic Dynamics in Systemic Inflammation
LPS‐induced systemic inflammation increases glymphatic influx but delays cervical lymphatic drainage, accompanied by AQP4 depolarization and impaired glymphatic clearance. Enhancing cerebral blood flow via the inotropic agent levosimendan effectively restored AQP4 polarization, improving glymphatic flux and amyloid‐β clearance.
Ruoyu Zhao +9 more
wiley +1 more source
Digitalis for treatment of heart failure in patients in sinus rhythm [PDF]
<b>Background</b><p></p> Digitalis glycosides have been in clinical use for the treatment of heart failure (HF) for longer than 200 years.
Dans, Antonio L +4 more
core +1 more source
Under hypoxia, HIF1A is directly bound to the PRELID2 promoter to increase PRELID2 pre‐mRNA expression, followed by the DYRK1A–SFPQ–SAM68 complex binding to Alu‐containing introns in PRELID2 pre‐mRNA, leading to circPRELID2 circularization. CircPRELID2 interacts with PCBP1 and promotes its cytoplasmic retention.
Pengshan Zhang +9 more
wiley +1 more source

